Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats

BACKGROUND: Erlotinib is an epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitor approved for treatment of non-small cell lung cancer. The wide inter-individual pharmacokinetic (PK) variability of erlotinib may impact treatment outcome and/or toxicity. Recent in vivo studies r...

Descripción completa

Detalles Bibliográficos
Autores principales: Amor, Dorra, Goutal, Sébastien, Marie, Solène, Caillé, Fabien, Bauer, Martin, Langer, Oliver, Auvity, Sylvain, Tournier, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095934/
https://www.ncbi.nlm.nih.gov/pubmed/30116910
http://dx.doi.org/10.1186/s13550-018-0434-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095934/
https://www.ncbi.nlm.nih.gov/pubmed/30116910
http://dx.doi.org/10.1186/s13550-018-0434-0

Ejemplares similares